Genomic, Immunological, and Clinical Characterization of Pyroptosis in Ovarian Cancer

References

• Kovacs SB, Miao EA. Gasdermins: effectors of pyroptosis. Trends Cell Biol. 2017;27(9):673–684. doi:10.1016/j.tcb.2017.05.005
   PubMed Web of Science ®Google Scholar
• Jorgensen I, Miao EA. Pyroptotic cell death defends against intracellular pathogens. Immunol Rev. 2015;265(1):130–142. doi:10.1111/imr.12287
   PubMed Web of Science ®Google Scholar
• Rébé C, Derangère V, Ghiringhelli F. Induction of pyroptosis in colon cancer cells by LXRβ. Mol Cell Oncol. 2015;Jan-Mar;2(1:e970094. doi:10.4161/23723548.2014.970094
   Google Scholar
• Karmakar M, Minns M, Greenberg EN, et al. N-GSDMD trafficking to neutrophil organelles facilitates IL-1β release independently of plasma membrane pores and pyroptosis. Nat Commun. 2020;11(1):2212. doi:10.1038/s41467-020-16043-9
   PubMed Web of Science ®Google Scholar
• Gao J, Qiu X, Xi G, et al. Downregulation of GSDMD attenuates tumor proliferation via the intrinsic mitochondrial apoptotic pathway and inhibition of EGFR/Akt signaling and predicts a good prognosis in non‑small cell lung cancer. Oncol Rep. 2018;40(4):1971–1984. doi:10.3892/or.2018.6634
   PubMed Web of Science ®Google Scholar
• Rogers C, Fernandes-Alnemri T, Mayes L, Alnemri D, Cingolani G, Alnemri ES. Cleavage of DFNA5 by caspase-3 during apoptosis mediates progression to secondary necrotic/pyroptotic cell death. Nat Commun. 2017;8:14128. doi:10.1038/ncomms14128
   PubMed Web of Science ®Google Scholar
• Jiang M, Qi L, Li L, Li Y. The caspase-3/GSDME signal pathway as a switch between apoptosis and pyroptosis in cancer. Cell Death Discovery. 2020;6:112. doi:10.1038/s41420-020-00349-0
   PubMed Web of Science ®Google Scholar
• Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression. Cancer Res. 2019;79(18):4557–4566. doi:10.1158/0008-5472.CAN-18-3962
   PubMed Web of Science ®Google Scholar
• Chen F, Zhuang X, Lin L, et al. New horizons in tumor microenvironment biology: challenges and opportunities. BMC Med. 2015;5(13):45. doi:10.1186/s12916-015-0278-7
   Google Scholar
• Orning P, Lien E, Fitzgerald KA. Gasdermins and their role in immunity and inflammation. J Exp Med. 2019;216(11):2453–2465. doi:10.1084/jem.20190545
   PubMed Web of Science ®Google Scholar
• Erkes DA, Cai W, Sanchez IM, et al. Mutant BRAF and MEK inhibitors regulate the tumor immune microenvironment via pyroptosis. Cancer Discov. 2020;10(2):254–269. doi:10.1158/2159-8290.CD-19-0672
   PubMed Web of Science ®Google Scholar
• Ye Y, Dai Q, Qi H. A novel defined pyroptosis-related gene signature for predicting the prognosis of ovarian cancer. Cell Death Discovery. 2021;7(1):71. doi:10.1038/s41420-021-00451-x
   PubMed Web of Science ®Google Scholar
• Jiang P, Gu S, Pan D, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550–1558. doi:10.1038/s41591-018-0136-1
   PubMed Web of Science ®Google Scholar
• Wang Q, Wang Y, Ding J, et al. A bioorthogonal system reveals antitumour immune function of pyroptosis. Nature. 2020;579(7799):421–426. doi:10.1038/s41586-020-2079-1
   PubMed Web of Science ®Google Scholar
• Tsuchiya K. Switching from apoptosis to pyroptosis: gasdermin-elicited inflammation and antitumor immunity. Int J Mol Sci. 2021;22(1):426. doi:10.3390/ijms22010426
   PubMed Web of Science ®Google Scholar
• Kossaï M, Leary A, Scoazec JY, Genestie C. Ovarian cancer: a heterogeneous disease. Pathobiology. 2018;85(1–2):41–49. doi:10.1159/000479006
   PubMed Web of Science ®Google Scholar
• Le Saux O, Ray-Coquard I, Labidi-Galy SI. Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer. Semin Cancer Biol. 2020;77:127–143. doi:10.1016/j.semcancer.2020.08.017
   PubMed Web of Science ®Google Scholar
• Jiménez-Sánchez A, Memon D, Pourpe S, et al. Heterogeneous tumor-immune microenvironments among differentially growing metastases in an ovarian cancer patient. Cell. 2017;170(5):927–38.e20. doi:10.1016/j.cell.2017.07.025
   PubMed Web of Science ®Google Scholar
• Roma-Rodrigues C, Mendes R, Baptista P, Fernandes A. Targeting tumor microenvironment for cancer therapy. Int J Mol Sci. 2019;20:4. doi:10.3390/ijms20040840
   Web of Science ®Google Scholar
• Belli C, Trapani D, Viale G, et al. Targeting the microenvironment in solid tumors. Cancer Treat Rev. 2018;65:22–32. doi:10.1016/j.ctrv.2018.02.004
   PubMed Web of Science ®Google Scholar
• Revythis A, Shah S, Kutka M, et al. Unraveling the wide spectrum of melanoma biomarkers. Diagnostics (Basel, Switzerland). 2021;11(8). doi:10.3390/diagnostics11081341.
   PubMedGoogle Scholar
• Boussios S, Karathanasi A, Cooke D, et al. PARP inhibitors in ovarian cancer: the route to “Ithaca”. Diagnostics (Basel, Switzerland). 2019;9(2):55.
   PubMedGoogle Scholar
• Li J, Wang J, Chen R, Bai Y, Lu X. The prognostic value of tumor-infiltrating T lymphocytes in ovarian cancer. Oncotarget. 2017;8(9):15621–15631. doi:10.18632/oncotarget.14919
   PubMedGoogle Scholar
• Nielsen JS, Sahota RA, Milne K, et al. CD20+ tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer. Clin Cancer Res. 2012;18(12):3281–3292. doi:10.1158/1078-0432.CCR-12-0234
   PubMed Web of Science ®Google Scholar
• Garris CS, Luke JJ. Dendritic cells, the T-cell-inflamed tumor microenvironment, and immunotherapy treatment response. Clin Cancer Res. 2020;26(15):3901–3907. doi:10.1158/1078-0432.CCR-19-1321
   PubMed Web of Science ®Google Scholar
• Henriksen JR, Nederby L, Donskov F, et al. Prognostic significance of baseline T cells, B cells and neutrophil-lymphocyte ratio (NLR) in recurrent ovarian cancer treated with chemotherapy. J Ovarian Res. 2020;13(1):59. doi:10.1186/s13048-020-00661-4
   PubMed Web of Science ®Google Scholar
• Tang R, Xu J, Zhang B, et al. Ferroptosis, necroptosis, and pyroptosis in anticancer immunity. J Hematol Oncol. 2020;13(1):110. doi:10.1186/s13045-020-00946-7
   PubMed Web of Science ®Google Scholar
• Yaghoubi N, Soltani A, Ghazvini K, Hassanian SM, Hashemy SI. PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer. Biomed Pharmacother. 2019;110:312–318. doi:10.1016/j.biopha.2018.11.105
   PubMed Web of Science ®Google Scholar
• Rotte A. Combination of CTLA-4 and PD-1 blockers for treatment of cancer. J Exp Clin Cancer Res. 2019;38(1):255. doi:10.1186/s13046-019-1259-z
   PubMed Web of Science ®Google Scholar
• Nguyen LT, Ohashi PS. Clinical blockade of PD1 and LAG3–potential mechanisms of action. Nat Rev Immunol. 2015;15(1):45–56. doi:10.1038/nri3790
   PubMed Web of Science ®Google Scholar
• Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1 checkpoint. Immunity. 2018;48(3):434–452. doi:10.1016/j.immuni.2018.03.014
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zhang Y, Xia S, et al. Gasdermin E suppresses tumour growth by activating anti-tumour immunity. Nature. 2020;579(7799):415–420. doi:10.1038/s41586-020-2071-9
   PubMed Web of Science ®Google Scholar
• Wang W, Green M, Choi JE, et al. CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy. Nature. 2019;569(7755):270–274. doi:10.1038/s41586-019-1170-y
   PubMed Web of Science ®Google Scholar
• Ai L. Xu A and Xu J. Roles of PD-1/PD-L1 pathway: signaling, cancer, and beyond. Adv Exp Med Biol. 2020;1248:33–59.
   PubMed Web of Science ®Google Scholar
• Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A. 2005;102(51):18538–18543. doi:10.1073/pnas.0509182102
   PubMed Web of Science ®Google Scholar
• González-Martín A, Sánchez-Lorenzo L. Immunotherapy with checkpoint inhibitors in patients with ovarian cancer: still promising? Cancer. 2019;125(Suppl 24):4616–4622. doi:10.1002/cncr.32520
   PubMedGoogle Scholar
• Zamarin D, Burger RA, Sill MW, et al. Randomized Phase II trial of nivolumab versus nivolumab and ipilimumab for recurrent or persistent ovarian cancer: an NRG oncology study. J Clin Oncol. 2020;38(16):1814–1823. doi:10.1200/JCO.19.02059
   PubMed Web of Science ®Google Scholar
• Strickland KC, Howitt BE, Shukla SA, et al. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget. 2016;7(12):13587–13598. doi:10.18632/oncotarget.7277
   PubMed Web of Science ®Google Scholar
• Boussios S, Karihtala P, Moschetta M, et al. Combined strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the treatment of ovarian cancer: a literature review. Diagnostics (Basel, Switzerland). 2019;9(3):5.
   Google Scholar
• Lu S, Stein JE, Rimm DL, et al. Comparison of biomarker modalities for predicting response to PD-1/PD-L1 checkpoint blockade: a systematic review and meta-analysis. JAMA Oncol. 2019;5(8):1195–1204. doi:10.1001/jamaoncol.2019.1549
   PubMed Web of Science ®Google Scholar
• Byun JM, Jeong DH, Choi IH, et al. The significance of VSIG4 expression in ovarian cancer. Int J Gynecol Cancer. 2017;27(5):872–878. doi:10.1097/IGC.0000000000000979
   PubMed Web of Science ®Google Scholar
• Dafou D, Grun B, Sinclair J, et al. Microcell-mediated chromosome transfer identifies EPB41L3 as a functional suppressor of epithelial ovarian cancers. Neoplasia (New York, NY). 2010;12(7):579–589. doi:10.1593/neo.10340
   PubMed Web of Science ®Google Scholar
• Heimes AS, Schmidt M, Jäkel J, et al. A retrospective analysis of immunohistochemically determined IRF4 (interferon regulating factor 4) expression in a consecutive cohort of 114 ovarian cancer patients. Arch Gynecol Obstet. 2019;299(1):239–246. doi:10.1007/s00404-018-4941-z
   PubMed Web of Science ®Google Scholar
• Yu J, Liu TT, Liang LL, et al. Identification and validation of a novel glycolysis-related gene signature for predicting the prognosis in ovarian cancer. Cancer Cell Int. 2021;21(1):353. doi:10.1186/s12935-021-02045-0
   PubMed Web of Science ®Google Scholar
• Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol. 2003;4(1):33–45. doi:10.1038/nrm1004
   PubMed Web of Science ®Google Scholar
• Martincuks A, Li PC, Zhao Q, et al. CD44 in ovarian cancer progression and therapy resistance-A critical role for STAT3. Front Oncol. 2020;10:589601. doi:10.3389/fonc.2020.589601
   PubMed Web of Science ®Google Scholar
• Jiang YX, Siu MK, Wang JJ, et al. Ascites-derived ALDH+CD44+ tumour cell subsets endow stemness, metastasis and metabolic switch via PDK4-mediated STAT3/AKT/NF-κB/IL-8 signalling in ovarian cancer. Br J Cancer. 2020;123(2):275–287. doi:10.1038/s41416-020-0865-z
   PubMed Web of Science ®Google Scholar
• Zhou J, Du Y, Lu Y, et al. CD44 expression predicts prognosis of ovarian cancer patients through promoting Epithelial-Mesenchymal Transition (EMT) by regulating snail, ZEB1, and Caveolin-1. Front Oncol. 2019;9:802. doi:10.3389/fonc.2019.00802
   PubMed Web of Science ®Google Scholar